Zentalis Pharmaceuticals (ZNTL) News Today $3.13 +0.03 (+0.97%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Zentalis appoints Chang as CPO, Wang as CBODecember 13, 2024 | markets.businessinsider.comZentalis Pharmaceuticals Announces Key Management AppointmentsDecember 12, 2024 | globenewswire.comFmr LLC Sells 3,600,886 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Fmr LLC reduced its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 41.5% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 5,075,837 shares of the company's stock after selling 3,600,886 shareDecember 11, 2024 | marketbeat.comVerition Fund Management LLC Has $5.54 Million Position in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Verition Fund Management LLC lifted its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 172.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,504,320 shares of the company's stock afDecember 3, 2024 | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 2, 2024 | globenewswire.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of "Hold" by AnalystsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received an average rating of "Hold" from the nine ratings firms that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating and four have issued a buy rating on the companNovember 29, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest UpdateZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the target of a significant drop in short interest during the month of November. As of November 15th, there was short interest totalling 4,970,000 shares, a drop of 29.5% from the October 31st total of 7,050,000 shares. Based on an average daily trading volume, of 2,060,000 shares, the short-interest ratio is currently 2.4 days.November 29, 2024 | marketbeat.comPrimecap Management Co. CA Buys 265,690 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Primecap Management Co. CA increased its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 21.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,498,030 shares of the company's stNovember 23, 2024 | marketbeat.comKuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law FirmNovember 21, 2024 | globenewswire.comWhat is HC Wainwright's Estimate for ZNTL Q3 Earnings?Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities researchers at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research note issued to investors on Friday, November 15th. HC Wainwright analyst A. Fein anticipates thNovember 18, 2024 | marketbeat.comFY2024 Earnings Forecast for ZNTL Issued By Leerink PartnrsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Research analysts at Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. Leerink Partnrs analyst A. BerenNovember 18, 2024 | marketbeat.comZentalis price target lowered to $8 from $12 at GuggenheimNovember 15, 2024 | markets.businessinsider.comGuggenheim Cuts Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target to $8.00Guggenheim decreased their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a report on Friday.November 15, 2024 | marketbeat.comCautious Hold on Zentalis Pharmaceuticals Amid Strategic Shifts and Safety ConcernsNovember 15, 2024 | markets.businessinsider.comZentalis Pharmaceuticals: Hold Rating Amid Leadership Changes and Awaited Strategic ClarityNovember 15, 2024 | markets.businessinsider.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $20.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday.November 15, 2024 | marketbeat.comWhat is Wedbush's Forecast for ZNTL FY2024 Earnings?Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Investment analysts at Wedbush boosted their FY2024 earnings per share estimates for shares of Zentalis Pharmaceuticals in a research note issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now expects that the company will pNovember 15, 2024 | marketbeat.comZentalis Pharmaceuticals: Strong Leadership and Promising Clinical Developments Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comZentalis Pharmaceuticals Announces New Leadership and Strategy ShiftNovember 14, 2024 | markets.businessinsider.comZentalis appoints Eastland as CEO, Bruns as CMO, Myers as ChairpersonNovember 13, 2024 | markets.businessinsider.comZentalis Pharmaceuticals Adds New Executives as Efforts Around Azenosertib SharpenNovember 13, 2024 | marketwatch.comGSA Capital Partners LLP Raises Stock Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)GSA Capital Partners LLP raised its position in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 138.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 608,585 shares of the company's stock after purchasing an additiNovember 12, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of "Hold" by BrokeragesShares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have earned an average rating of "Hold" from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation and three have issued a bNovember 4, 2024 | marketbeat.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 1, 2024 | globenewswire.comState Street Corp's Strategic Reduction in Zentalis Pharmaceuticals HoldingsOctober 18, 2024 | finance.yahoo.comSeveral Insiders Invested In Zentalis Pharmaceuticals Flagging Positive NewsOctober 15, 2024 | uk.finance.yahoo.comShort Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Drops By 26.2%Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totalling 8,640,000 shares, a drop of 26.2% from the September 15th total of 11,700,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the days-to-cover ratio is currently 4.9 days.October 12, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Recommendation of "Hold" by BrokeragesShares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) have been given a consensus recommendation of "Hold" by the ten analysts that are covering the firm, MarketBeat reports. Seven analysts have rated the stock with a hold rating and three have assigned a buy rating to the compOctober 10, 2024 | marketbeat.comFMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals IncOctober 7, 2024 | gurufocus.comZentalis Pharma (NASDAQ:ZNTL) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Holdings Raised by Renaissance Technologies LLCRenaissance Technologies LLC lifted its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 152.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 661,682October 1, 2024 | marketbeat.comDecheng Capital LLC Buys 970,859 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)Decheng Capital LLC lifted its stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 46.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,070,442 shares of the company's stock after buying an addiSeptember 26, 2024 | marketbeat.comXTX Topco Ltd Has $730,000 Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)XTX Topco Ltd lifted its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 1,581.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 178,465 shares of the company's stock after purchasing aSeptember 23, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Sold by Federated Hermes Inc.Federated Hermes Inc. lowered its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 75.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 482,481 shares of the company's stock after selling 1,516,219 shares during tSeptember 21, 2024 | marketbeat.comBiotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on UpdatesSeptember 19, 2024 | msn.comFDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitorSeptember 18, 2024 | msn.comMaintaining Hold on Zentalis Pharmaceuticals Amidst Positive Regulatory Developments and Upcoming Clinical MilestonesSeptember 18, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)September 18, 2024 | markets.businessinsider.comZentalis Pharma (NASDAQ:ZNTL) Stock Quotes, Forecast and News SummarySeptember 17, 2024 | benzinga.comKuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law FirmSeptember 16, 2024 | prnewswire.comZentalis Shares Rise After U.S. FDA Lifts Hold on Azenosertib StudiesSeptember 16, 2024 | marketwatch.comWhy Zentalis Pharmaceuticals Is Rising In Pre-market?September 16, 2024 | markets.businessinsider.comZentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Reaffirmed by OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday.September 16, 2024 | marketbeat.comTraders Buy High Volume of Zentalis Pharmaceuticals Call Options (NASDAQ:ZNTL)Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) saw some unusual options trading on Monday. Investors purchased 3,891 call options on the company. This represents an increase of approximately 5,886% compared to the average volume of 65 call options.September 16, 2024 | marketbeat.comFDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological CancersSeptember 16, 2024 | benzinga.comZentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib StudiesSeptember 16, 2024 | globenewswire.comTD Asset Management Inc Decreases Stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)TD Asset Management Inc lowered its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 60.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,880 shares of the company's stock after sellingSeptember 16, 2024 | marketbeat.comZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Recommendation of "Hold" from AnalystsZentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has received a consensus recommendation of "Hold" from the ten ratings firms that are currently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a hold rating and three have assigned a buy ratingSeptember 15, 2024 | marketbeat.comZentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024September 9, 2024 | globenewswire.comZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 3, 2024 | globenewswire.com Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking. Click here and I’ll show you exactly how to position your money ZNTL Media Mentions By Week ZNTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZNTL News Sentiment▼0.560.69▲Average Medical News Sentiment ZNTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZNTL Articles This Week▼23▲ZNTL Articles Average Week Get Zentalis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ZNTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NUVB News Today AVBP News Today IMTX News Today REPL News Today QURE News Today ETNB News Today PLRX News Today RLAY News Today AVXL News Today IMNM News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZNTL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my f...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zentalis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zentalis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
